Real-Time Data. Real-World Impact.
0 likes23 views
The document outlines how Covance utilizes real-time data to enhance patient recruitment for clinical trials, significantly improving key metrics such as enrollment timelines and investigator performance. By leveraging various data sets and making minor protocol adjustments, Covance helped increase eligible patient populations while maintaining trial integrity. The report highlights successful case studies demonstrating accelerated site start-up and reduced clinical costs across multiple indications.
Real-Time Data. Real-World Impact.
- 1. REAL-TIME REAL-WORLD SEE THE REAL-WORLD IMPACT FOR YOURSELF. WE DON’T JUST TALK ABOUT DATA. WE SHOW RESULTS.
- 2. A DIRECT CONNECTION TO FINDING POTENTIAL CLINICAL TRIAL PARTICIPANTS CLIENT CHALLENGE CLIENT CHALLENGE REAL-WORLD IMPACT REAL-WORLD IMPACT Month 1 Results: 4,829 patients emailed, 523 visited the study website, 7 consented, 6 completed Patient Service Center (PSC) blood draws Difficulty recruiting patients for a virtual study with a PSC blood draw Extremely tight turnaround times for launching email campaigns and boosting recruitment PROTOCOL DESIGN TO MAXIMIZE PATIENT ENROLLMENT OPPORTUNITY Result: The eligible patient population increased by +50% without compromising the objectives of the trial. Analyzed LabCorp de-identified clinical laboratory data to discern whether small protocol changes could accelerate recruitment. Data helped to identify that making minor changes to the eGFR cutoff would increase the patient pool size, therefore reducing recruitment timelines. Study to test if a drug reduced progression of kidney disease in patients with Type II diabetes Study was looking for a small subset of patients which represented <7% of patients Leveraged LabCorp database to find potential patients in key geographies as specified by the client. LabCorp sent emails with study specific website links to targeted patient populations. Seeking patients with a history of stroke or cardiovascular event ~150 Million Lives >150 million patients >30 billion test results >
- 3. INCORPORATING THE PATIENT VOICE CLIENT CHALLENGE CLIENT CHALLENGE REAL-WORLD IMPACT REAL-WORLD IMPACT Result: Conducted research with 320 Ulcerative Colitis patients to design a study to meet the client’s needs. Extended the known investigator database for Ulcerative Colitis with available capacity. Leveraged Covance Patient Intelligence Database to improve patient recruitment and retention rates. Identified investigator best- suited to run Ulcerative Colitis studies with available capacity. Limited patient population due to competing studies and the fact that 90% of patients don’t participate in clinical trials Difficulty finding, productive investigators for study in a highly competitive space EXCEEDING RECRUITMENT GOALS FOR A GLOBAL MULTI-STUDY REGISTRATION PROGRAM Result: Achieved “first patient in” (FPI) requirement ahead of schedule for all studies in the program. Beat historical industry performance across a number of key metrics: 18% fewer weeks from final protocol to FPI | 75% more high-performing sites 31% more patients/site/month | 41% fewer non-performing sites Randomize 2,700 patients within a very narrow timeframe for a suite of registration studies Get all sites across the globe up and running as quickly as possible Leveraged Xcellerate® historical investigator database to identify and secure highest performing investigators in indication. Based on extensive feasibility outreach and site capacity assessment, efficiencies were identified that allowed effective overlapping of sites across the program resulting in accelerated site start-up and reduced clinical costs. 90% ~30countries >20 indications >175k unique investigators >15k protocols
- 4. *Average time savings based on an analysis of trials processed through Covance Central Labs with Protocol Finalization date after 1/1/2009 for the specific clinical indications. Past performance is not a guarantee of future results, and a variety of factors other than CRO performance can impact timing of clinical studies. Covance is the drug, medical device and diagnostics business segment of LabCorp, a leading global life sciences company. COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world. The Americas +1.888.COVANCE (+1.888.268.2623) +1.609.452.4440 Europe/Africa +00.800.2682.2682 +44.1423.500888 Asia Pacific +800.6568.3000 +65.6.5686588 © Copyright 2019 Covance Inc. BROCVD018-1019 REAL-TIME DATA. REAL-WORLD IMPACT. Talk to a representative to find out how Covance can impact your studies. LEARN MORE AT COVANCE.COM/REALIMPACT COVANCE DATA CAN HELP ACCELERATE YOUR STUDIES. Covance data is comprised of four powerful data sets: LabCorp De-Identified Lab Result Data, Covance Central Labs Investigator Data, Patient Direct and Patient Intelligence. The combination of these data sets provides unique insights, enabling us to deliver strong, viable protocol designs for faster patient enrollment, more patients per site and fewer non-performing sites than the industry average. By increasing forecast accuracy, you can minimize study costs and speed time to market. SITE ACTIVATION TO LAST PATIENT IN Number of Months* MONTHS FASTER CARDIOVASCULAR3.1 MARKET 12.92 MONTHS COVANCE 9.85 MONTHS 5.0 MARKET 14.88 MONTHS COVANCE 9.94 MONTHS MONTHS FASTER NEUROLOGY 3.3 MARKET 18.66 MONTHS COVANCE 15.41 MONTHS MONTHS FASTER HEMATOLOGY 4.2 MARKET 20.99 MONTHS COVANCE 16.80 MONTHS MONTHS FASTER ONCOLOGY